Abstract
Programmed cell death 1 (PD-1) plays an important pathologic role in sepsis-induced immunosuppression. However, whether PD-1 overexpression occurs early during septic shock is unknown and its regulation mechanism is also unknown. Our study investigated the expressions of PD-1/programmed death-ligand 1 (PD-L1) on immune cells in peripheral blood from the early-stage septic shock patients. We found that both PD-1 and PD-L1 showed increased expressions on the CD4+ T cells and monocytes. It indicated that PD-1 expression might be an early biomarker to assess illness severity and predict the prognosis of septic shock. Then, we further investigated the mechanism underlying the regulation of PD-1 expression. Our data showed that Notch signaling pathway was activated in both septic shock patients and lipopolysaccharide- (LPS-) tolerant THP1 cells and both interleukin-10 (IL-10) and PD-1 were increased in the THP1 cells. Inhibition of Notch signaling by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenyl glycinet-butyl ester (DAPT) induced significantly decreased expressions of PD-1 and IL-10 in the LPS-tolerant cell model. Our work suggested that Notch signaling pathway was involved in the regulation of PD-1 expression.
Highlights
Sepsis, a systemic inflammatory response to infection, is one of the most challenging clinical problems worldwide and the leading cause of death in noncoronary ICUs [1]
First we investigated the expressions of PD1/programmed death-ligand 1 (PD-L1) on both CD4+ T cells and monocytes from peripheral blood in the early-stage septic shock patients and showed the relationship between Programmed cell death 1 (PD-1)/PD-L1 and clinical outcomes
Patients with septic shock showed increased numbers of white blood cells compared to healthy volunteers. 29 septic shock patients were infected with Gram-negative bacilli, 22 patients were infected with Gram-positive cocci, and 5 patients were infected with fungi
Summary
A systemic inflammatory response to infection, is one of the most challenging clinical problems worldwide and the leading cause of death in noncoronary ICUs [1]. Patients in the immunosuppressive phase of sepsis are often unable to control the primary infection and may acquire a secondary infection during hospitalization This phenomenon has recently been identified as an important cause of mortality during sepsis [3]. Tregs are involved in the regulation of peripheral tolerance which demonstrated again that immunosuppression was a key factor in the development of sepsis [5, 6]. All these suggested that understanding the mechanism underlying the immunosuppression will help to identify the novel targets in the treatment of sepsis
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have